Based on these metrics, I would recommend HOLD SUNPHARMA, as the stock's 12-month return is positive, indicating a strong long-term performance, and the Sharpe Ratio suggests that the returns are not overly risky. However, the recent 6-month and 3-month returns are subdued, indicating some short-term caution is warranted.